Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults

Modern cell culture-based technology eliminates vaccine manufactures reliance on embryonated chicken eggs, which may become compromised during an avian influenza pandemic. Four studies (total N = 6230) assessed the immunogenicity and safety of mammalian cell-based, MF59(®)-adjuvanted, A/H5N1 vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Versage, Eve, van Twuijver, Esther, Jansen, Wim, Theeuwes, Ad, Sawlwin, Daphne, Hohenboken, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704792/
https://www.ncbi.nlm.nih.gov/pubmed/34960214
http://dx.doi.org/10.3390/vaccines9121468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704792/
https://www.ncbi.nlm.nih.gov/pubmed/34960214
http://dx.doi.org/10.3390/vaccines9121468

Ejemplares similares